Current pharmaceutical design , 20 (7), 1126-35
Its 2030-hour half-life means that a single administration produces a prolonged elevation of free IGF1R-binding peptide, making it well-suited for in vivo anabolic or metabolic studies in which continuous infusion is impractical
As the WL achieved with the novel obesity pharmacotherapies approaches that of bariatric surgery, we will need to assess whether long-term complications observed after bariatric surgery such as increased risk of osteoporosis, fractures, macro- and micronutrient deficiencies as well as self-harm behaviours will also be present with pharmacotherapy [112, 113]
Injection-based therapies are not universally appropriate
If they do and the clinical picture improves, that is not proof, but it is meaningful signal
A protein catalytic framework with an N-terminal nucleophile is capable of self-activation